Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Trial of Early Aggressive Drug Therapy in Juvenile Idiopathic Arthritis
This study is currently recruiting participants.
Study NCT00443430 Information provided by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
First Received: March 2, 2007 Last Updated: April 8, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Juvenile Idiopathic Arthritis
Juvenile Rheumatoid Arthritis
Additional conditions recognized in this trial
Arthritis
Arthritis, Juvenile Rheumatoid
Arthritis, Rheumatoid
More general conditions related to this trial
Autoimmune Diseases
Connective Tissue Diseases
Immune System Diseases
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Interventions listed in this trial
methotrexate
Additional drug interventions recognized in this trial
Methylprednisolone
Methylprednisolone acetate
Methylprednisolone Hemisuccinate
Prednisolone
Prednisolone acetate
TNFR-Fc fusion protein
More general drug interventions related to this trial
Abortifacient Agents
Abortifacient Agents, Nonsteroidal
Analgesics
Analgesics, Non-Narcotic
Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal
Antiemetics
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Antirheumatic Agents
Autonomic Agents
Central Nervous System Agents
Dermatologic Agents
Enzyme Inhibitors
Folic Acid Antagonists
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Neuroprotective Agents
Nucleic Acid Synthesis Inhibitors
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Reproductive Control Agents
Sensory System Agents
Therapeutic Uses
Sponsors listed in this trial
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Amgen
Back to top of Main Content
